Neurodegeneration and Neuroprotection in Parkinson's Disease

Neurodegeneration and Neuroprotection in Parkinson's Disease

1st Edition - April 17, 1996

Write a review

  • Editors: C. Olanow, Peter Jenner, Moussa Youdim
  • eBook ISBN: 9780080537412

Purchase options

Purchase options
DRM-free (PDF)
Sales tax will be calculated at check-out

Institutional Subscription

Free Global Shipping
No minimum order

Description

Neuroscience Perspectives provides multidisciplinary reviews of topics in one of the most divers and rapidly advancing fields in the life sciences. Whether you are a new recruit to neuroscience, or an established expert, look to this series for 'one-stop' sources of the historical, physiological, pharmacological, biochemical, molecular biological, and therapeutic aspects of chosen research areas.

Readership

Ideal for research-level neuroscientists, pharmacologists, and neurologists from post-graduate to senior scientists in academia and industry. There is also potential for special sales to pharmaceutical companies.

Table of Contents

  • Oxidant Stress:
    J.M.C. Gutteridge and B. Halliwell, Oxidative Stress, Brain Iron, and Neurodegeneration: Basic Principles.
    P. Jenner and C.W. Olanow, Pathological Evidence for Oxidative Stress in Parkinson's Disease and Related Degenerative Disorders.
    K. Kieburtz and I. Shoulson, Treatment of Parkinson's Disease with Deprenyl (Selegiline) and Other Mondamine Oxidase Inhibitors.
    C.W. Olanow and M.B.H. Youdim, Iron and Nuerodegeneration: Prospects for Neuroprotection.
    R.A. Floyd and J.M. Carney, Nitrone Radical traps (NRTs) Protect in Experimental Neurodegenerative Diseases.
    M. Flint Beal, Therapeutic Effects of NOS Inhibition in Neuronal Injury. Mitochodrial Toxicity:
    A.H.V Schapira, Mitochondrial Dysfunction in Neurodegeneration: Prospects for Neuroprotection.
    Excitatory Neurotoxicity:
    J.G. Greene and J.T. Greenamyre, Bioenergetics and Exitotoxicity: The Weak Excitotoxic Hypothesis.
    Calcium Exitatory Toxicity:
    P. Nicotera and S. Orrenius, Calcium Ions in Necrotic and Apoptotic Cell Death. Trophic Factors:
    C.A. Altar, S.J. Wiegand, R.M. Lindsay, and J.M. Cedarbaum, Neurotrophic Factors: Towards a Restorative Therapy of Parkinson's Disease.
    Immune Mechanisms:
    S.H. Appel, R.G. Smith, and W.D. Le, Immuno-Mediated Cell Death and Neuroprotection in Neurodegenerative Diseases.
    Apoptosis:
    W.G. Tatton, M.Y.H. Ju, J. Wadia, and N.A. Tatton, Reduction of Neuronal Apoptosis by Small Molecules: Promise for New Approaches to Neurological Therapy. Subject Index.

Product details

  • No. of pages: 224
  • Language: English
  • Copyright: © Academic Press 1996
  • Published: April 17, 1996
  • Imprint: Academic Press
  • eBook ISBN: 9780080537412

About the Series Volume Editors

C. Olanow

Affiliations and Expertise

Mount Sinai Medical Center, New York, U.S.A.

Peter Jenner

Professor Peter Jenner is a specialist in preclinical aspects of neurodegenerative diseases, notably Parkinson’s disease. He has spent the major part of his career at King’s College London where he was Head of Pharmacology for 14 years before returning to his research roots and subsequently becoming Emeritus Professor of Pharmacology. Peter has expertise in drug metabolism and pharmacokinetics but neuropharmacology based on functional models of neurodegenerative diseases has formed the major focus of his work. Peter holds a BPharm, PhD and DSc degree from the University of London. He has published well over 1000 articles with more than 700 peer reviewed papers. He is a Fellow of the Royal Pharmaceutical Society, the British Pharmacological Society, the Royal Society of Medicine and of King’s College London. Peter was recently honoured with a Doctor Honoris Causa degree from Carol Davila University of Medicine and Pharmacy, Bucharest and made an Honorary Fellow of The British Pharmacological Society for his contribution to research in to movement disorders. Peter has worked closely with the pharmaceutical industry for many years and acts as an adviser and consultant to both major pharma and biotech companies. He has a wide knowledge of the drug discovery and drug development process and has been involved from molecule synthesis through to drug registration for use in man. Peter was the Founder, Director and Chief Scientific Officer of Proximagen, a biotech focussed on the treatment and cure of neurodegenerative diseases that was listed on AIMs and subsequently purchased by a US based healthcare company. He is a regular speaker at international meetings and also takes time to speak at Parkinson’s disease patient-carer groups across the UK.

Affiliations and Expertise

Emeritus Professor of Pharmacology, Institute of Pharmaceutical Sciences, King’s College London, London, UK

Moussa Youdim

Affiliations and Expertise

Technion-Israel Institute of Technology, Haifa, Israel

Ratings and Reviews

Write a review

There are currently no reviews for "Neurodegeneration and Neuroprotection in Parkinson's Disease"